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Objectives: Mutations in the gyrase genes cause fluoroquinolone resistance in Mycobacterium tuberculosis.
However, the predictive value of these markers for clinical outcomes in patients with MDR-TB is unknown to
date. The objective of this study was to determine molecular markers and breakpoints predicting second-line
treatment outcomes in M. tuberculosis patients treated with fourth-generation fluoroquinolones.
Methods:Weanalysed treatment outcome data in relation to the gyrA and gyrB sequences andMICs of ofloxacin,
gatifloxacin and moxifloxacin for pretreatment M. tuberculosis isolates from 181 MDR-TB patients in Bangladesh
whose isolates were susceptible to injectable drugs.
Results: The gyrA 90Val, 94Gly and 94Ala mutations were most frequent, with the highest resistance levels for
94Gly mutants. Increased pretreatment resistance levels (.2 mg/L), related to specific mutations, were asso-
ciated with lower cure percentages, with no cure in patients whose isolates were resistant to gatifloxacin at
4 mg/L. Any gyrA 94 mutation, except 94Ala, predicted a significantly lower proportion of cure compared with
all other gyrA mutations taken together (all non-94 mutants+94Ala) [OR¼4.3 (95% CI 1.4–13.0)]. The differ-
ence in treatment outcome was not explained by resistance to the other drugs.
Conclusions: Our study suggests that gyrAmutations at position 94, other than Ala, predict high-level resistance
to gatifloxacin and moxifloxacin, as well as poor treatment outcome, in MDR-TB patients in whom an injectable
agent is still effective.
Introduction
Fluoroquinolones (FQs) are the most important drugs in the
treatment of MDR-TB. Phenotypic cross-resistance between
FQs has been extensively documented, and breakpoints of newer,
fourth-generation FQs (moxifloxacin and gatifloxacin) have been
calibrated against older FQs (usually ofloxacin1–6 or levofloxacin).
Independent of the medium, MICs of the newer FQs are consider-
ably lower than those of the older ones,2,6–11and theymay remain
clinically useful even in the presence of low-level resistance.12–14
Genotypic determinants of resistance to specific drugs or drug
classes offer a rapid and highly specific alternative to phenotypic
drug susceptibility testing (DST). The majority of mutations
found in the quinolone resistance-determining region (QRDR) of
the gyrA gene have been correlated with FQ resistance both in
laboratory-generated and clinicalMycobacterium tuberculosis iso-
lates.4,5,10,15–21Two raregyrAmutationswithin theQRDR (Thr80Ala
and Ala90Gly) do not confer resistance and, in combination, may
even increase in vitro susceptibility,7,22 while other mutations con-
stitute phylogenetic markers (95Thr)22,23 without effect on
MICs. In some instances, gyrBmutations have been associated
with FQ resistance, mainly at codons 538–540 following the
TubercList nomenclature,3,17,22,24,25 yet the majority of
observed gyrB mutations do not confer phenotypic resistance.22,26
Clinical evidence to support the hypothesis that the greater
in vitro activity of newer FQs can overcome resistance to older
FQs is sparse.10 In a retrospective study on 106 MDR-TB patients,
levofloxacin proved superior to ofloxacin even for ofloxacin-
resistant strains (2 mg/L).12 Similarly, moxifloxacin and levofloxa-
cin showed equivalent efficacy in the treatment of 171 MDR-TB
patients in South Korea.27 In the mouse model, moxifloxacin
had greater sterilizing activity than levofloxacin in MDR-TB treat-
ment.28 Furthermore, 800 mg/kg moxifloxacin demonstrated
good efficacy for treatment of mice infected with low-level
moxifloxacin-resistant strains (MICof 0.5 mg/L) and reducedmor-
tality for intermediately resistant strains (2 mg/L), but had no
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impact on high-level resistant strains (4 mg/L).13 Treatment with
a 9 month gatifloxacin-based regimen showed that, in contrast to
high-level resistance, low-level gatifloxacin resistance did not
adversely affect treatment outcome.14
Nevertheless, the critical threshold drug concentration for
fourth-generation FQs above which successful treatment out-
come becomes unlikely remains unknown. Moreover, the strength
of the association of mutations in the QRDR with treatment out-
come remains largely elusive.
The purpose of this study was to identify the MIC breakpoints
and the gyrA and gyrBmutations predicting poor clinical outcome
with standardized FQ-based MDR treatment regimens.
Methods
Study population and isolates
Isolates from patients with confirmed MDR-TB in the Damien Foundation
Bangladesh project are routinely shipped to the Institute of Tropical
Medicine in Antwerp for second-line DST and storage at 2808C. During
the study period, a total of 1037 MDR-TB patients were treated with
ofloxacin-based (n¼240) or gatifloxacin-based (n¼797) standard regi-
mens. In this study, we included all available MDR isolates found to be
ofloxacin-resistant in routine testing, together with a random sample of
ofloxacin-susceptible MDR-TB isolates from the same site, representing
294 patients. From 2005 to 2010, 61 ofloxacin-resistant and 171 ofloxacin-
susceptible MDR-TB isolates had their ofloxacin, gatifloxacin and moxifloxa-
cin MICs determined and gyrA and gyrB sequenced (Figure 1). From 2010
onwards, 95 ofloxacin-resistant isolates were available and had the gati-
floxacin MIC determined, as well as gyrA and gyrB sequencing done. In
total, 327 MDR-TB isolates were examined from 294 patients.
Subsequent to ofloxacin-based regimens for the treatment of MDR, a
9 monthMDR treatment regimenwas implemented in this area, with high-
dose gatifloxacin, ethambutol, pyrazinamide and clofazimine throughout,
supplemented during the minimum 4 month intensive phase by kanamy-
cin, prothionamide and isoniazid, colloquially also referred to as the
‘Bangladesh regimen’. Deviations from this standard regimen were kept
minimal, such as stopping prothionamide early, or switching to intermit-
tent kanamycin injections. Gatifloxacin doses given were 400 mg for
patients weighing ,33 kg, 600 mg for those between 33 and 50 kg and
800 mg for those.50 kg, in combination with six other drugs in the inten-
sive phase.29 The bacteriological response was ascertained by sputum
smear microscopy and solid-medium-based culture.
The impact of pre-existing FQ resistance on treatment outcome was
determined for patients with an FQ-resistant baseline isolate available and
bacteriologically defined outcome (cure, failure or relapse) who received
the high dose of gatifloxacin. Patients who died or were lost to follow-up,
and also those who had documented resistance to second-line injectables
(XDR), were excluded from the outcomeanalysis. Outcome—including ascer-
tainment for relapse during 2 years post-treatment follow-up—was defined
following WHO guidelines.30 To declare cure required completion of treat-
ment with five or more negative cultures after the last positive culture.
Failure was defined as one or more positive cultures from the fifth month
of treatment onwards and relapse as at least one positive culture during
the follow-up period. Reclassification of failure or relapse as reinfection or
laboratory error (cross-contamination, misidentification) required genotypic
confirmation (by spoligotyping and/or 15-locus mycobacterial interspersed
repetitive unit–variable number of tandem repeat typing) of strain difference.
Phenotypic DST
Routine DST was done by the proportion method on Lo¨wenstein–Jensen
(LJ) medium using established critical concentrations (rifampicin,
40 mg/L; isoniazid, 0.2 and 1 mg/L; ethambutol, 0.2 mg/L) and
Middlebrook 7H11 medium (ofloxacin, 2 mg/L; kanamycin, 6 mg/L; ethio-
namide, 10 mg/L).31 Ethionamide was used as surrogate for prothiona-
mide (used in the regimen).
The MICs of ofloxacin, gatifloxacin and moxifloxacin were determined
on LJ medium using the following concentrations: 0.5, 1, 2, 4 and 8 mg/L
for ofloxacin and 0.25, 0.5, 1, 2, 4, 8 and 16 mg/L for gatifloxacin andmoxi-
floxacin.31–33 The MIC-99 (henceforth MIC) was the lowest drug concen-
tration determined to inhibit 99% of visible bacillary growth. To this end,
drug-containing slants and one control tube were inoculated with a
1021 dilution of a 1 mg/mL bacterial suspension and a second control
tube using a 1023 dilution. All tubes were inspected for growth after 4
and 6 weeks of incubation at 34–388C.
Isolates with anMICvalue less than or equal to the set breakpoint were
considered susceptible; MIC values greater than the breakpoint were
defined as resistant.
Sequence analysis
DNA extractions were prepared by resuspending a loopful of bacilli in
200 mL of Tris/EDTA buffer [10 mM Tris–HCl/1 mM EDTA (pH 8.0)], followed
DF Bangladesh
Culture on LJ
ITM Antwerp
Routine DST
Patients with OFX-
susceptible isolates
Patients with OFX-
resistant  isolates
MIC OFX, GAT, MXF
gyrAB sequencing
MIC GAT
gyrAB sequencing
MIC comparison (n = 228)
GAT MIC versus gyrAB (n = 327)
Treatment outcome analysis
GAT treatment
Versus MIC (n = 161)
Versus gyrAB (n = 181)
Pretreatment isolates only
GAT treatment only
(n = 223)
Exclusion:
- modiﬁed treatment (21)
- initial KAN resistance (5)
- died or abandonded (14)
- no sequence data (2)
MDR isolates
2005–10
(n = 171) (n = 61)
2010 onwards
Selection GAT treatment
(n = 95)
Figure 1. Overview of patients and M. tuberculosis complex isolates
included. DF, Damien Foundation; ITM, Institute of Tropical Medicine;
OFX, ofloxacin; GAT, gatifloxacin; MXF, moxifloxacin; KAN, kanamycin.
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by heat inactivation at 1008C for 5 min and centrifugation at 10000 g for
15 s. Two microlitres of supernatant was used for combined amplification
of gyrA and gyrB as described previously.7
For pyrazinamide and clofazimine susceptibility testing, sequencing of
the pncA and Rv0678 genes, respectively, was performed in a similar way,
using primer pairs pncA-R (5- CGACCTGGAAAGGCAACCCGAGAG-3)/pncA-S
(5-CGCCCGATGAAGGTGTCGTAGAAGC-3) and 30F22 (5-AGCCGGAAACTTC
GTACTCCAC-3)/916R20 (5-GCTGGACAACACGGTCACCT-3), yielding ampli-
cons of 1163 and 886 bp, respectively. After purification using the
ExoSAP-ITw Kit (USB Corporation), sequencing was done using a capillary
sequencer (Applied Biosystems 3730 DNA Analyzer) in combination with
an ABI Prism BigDye Terminator Cycle Sequencing Kit. Any Rv0678 mutant
was considered as potentially causing clofazimine resistance. For pyrazina-
mide, known resistance-conferring pncAmutations plus all novel mutations
in the pncA gene not previously described were considered as resistant.34,35
CLC Sequence Viewer (version 7.0.1) was used for analysis. Mutations
were identified using NCBI BLAST and comparing with the M. tuberculosis
H37Rv sequence (GenBank accession number NC_000962). An isolate was
defined as heteroresistant if both WT and mutant nucleotides conferring
resistance at a specific locus were detected.
Data analysis
The primary data were read into an EpiData file for analysis (EpiData
Analysis, version 2.2.2.183, freely available at http://www.epidata.dk). To
determine differences between observed values, x2 values, ORs and
95% CIs for categorical data were calculated. Additional analyses were
done with R software (R Core Team 2015; http://www.R-project.org). For
contingency tables with nominal values (levels of drug concentrations)
we calculated Cramer’s V (a Pearson’s x2-derived statistic) as themeasure
of association. To calculate the MIC ratios between ofloxacin and gati-
floxacin and between ofloxacin and moxifloxacin, we applied a censored
Tobit regression, with gatifloxacin or moxifloxacin, respectively, being the
dependent right-censored variable above an MIC of 4 mg/L.
Ethics considerations
Ethics clearance for the treatment regimens was obtained from the
Bangladesh Medical Research Council (reference BMRC/ERC/2004-2007/
1130). Before enrolment, each patient completed and signed an informed
consent form in the local language. Ethics clearance for the retrospective
Table 1. Correlation between FQ MICs for 228 M. tuberculosis isolates from patients prior to initiation and during follow-up of second-line treatment:
ofloxacin versus gatifloxacin, ofloxacin versus moxifloxacin and gatifloxacin versus moxifloxacin
OFX MIC (mg/L)
GAT MIC (mg/L)
≤0.25 0.5 1 2 4 8 .8 total
≤0.5 12 0 0 0 0 0 0 12
1 83 2 0 0 0 0 0 85
2 59 16 0 0 0 0 0 75
4 1 8 1 0 0 0 0 10
8 0 1 12 3 2 0 0 18
.8 0 0 6 4 5 0 13 28
Total 155 27 19 7 7 0 13 228
OFX MIC (mg/L)
MXF MIC (mg/L)
≤0.25 0.5 1 2 4 8 .8 total
≤0.5 12 0 0 0 0 0 0 12
1 75 10 0 0 0 0 0 85
2 35 33 7 0 0 0 0 75
4 0 7 3 0 0 0 0 10
8 0 1 5 10 1 1 0 18
.8 0 0 2 7 2 3 14 28
Total 122 51 17 17 3 4 14 228
GAT MIC (mg/L)
MXF MIC (mg/L)
≤0.25 0.5 1 2 4 8 .8 total
≤0.25 120 33 2 0 0 0 0 155
0.5 2 17 7 1 0 0 0 27
1 0 1 7 11 0 0 0 19
2 0 0 1 5 1 0 0 7
4 0 0 0 0 2 4 1 7
8 0 0 0 0 0 0 0 0
.8 0 0 0 0 0 0 13 13
Total 122 51 17 17 3 4 14 228
OFX, ofloxacin; GAT, gatifloxacin; MXF, moxifloxacin.
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sub-study on the M. tuberculosis isolates was obtained from the Institute
of Tropical Medicine Institutional Review Board (reference 833/12).
Results
A total of 228 isolates were available for MIC comparison between
ofloxacin, gatifloxacin andmoxifloxacin (Figure 1). The MICs of the
three FQs were strongly correlated (Cramer’s V: 0.555, 0.539 and
0.737, respectively, for ofloxacin versus gatifloxacin, ofloxacin
versus moxifloxacin and gatifloxacin versus moxifloxacin), with
ofloxacin MICs being systematically and significantly higher rela-
tive to gatifloxacin (Table 1). Censored regression analysis revealed
a linear correlation between the logarithms of the ofloxacin
and gatifloxacin MICs, with the gatifloxacin/ofloxacin MIC ratio
(converted back to linear scale) increasing from 3.4 to 5.7 as the
gatifloxacin MICs increased from 0.25 to 4 mg/L (Figure 2). Similar
MIC ratios and a linear correlation were observed between ofloxa-
cin and moxifloxacin, with a linearized ratio ranging from 3.2 to
4.7 (Figure 2). Moxifloxacin MICs were somewhat higher than
those of gatifloxacin (steeper regression slope of moxifloxacin
MICs: conc[gatifloxacin]¼exp(21.482+0.808*ln(ofloxacin)) vs
conc[moxifloxacin]¼exp(21.353+0.866*ln(ofloxacin))) (Figure 2).
For all isolates tested, theMICs ofmoxifloxacin and gatifloxacin
were identical in 62.0%, while 35.0% had a 2-fold higher moxi-
floxacin MIC and in only 2.8% was the moxifloxacin MIC below
that of gatifloxacin. These higher MICs of moxifloxacin relative
to gatifloxacin were not related to specific mutations, and
occurred mostly among the lower MIC values.
A comparison between gatifloxacin MICs and gyrAB sequence
data was made for 327 isolates (Figure 1 and Table 2). In 119 of
327 isolates we observed mutations in the QRDRs: 6 gyrB
mutants, 96 gyrA mutants, 6 with mutations in both genes, 10
showing heterogeneity in the gyrA gene and 1 showing hetero-
geneity in the gyrB gene. In addition to QRDR mutations, we
observed one deletion of codons 683 and 684 in gyrB, one
615Cys mutation and six isolates showing a 551Arg mutation.
All of these had gatifloxacin and moxifloxacin MIC values
≤0.25 mg/L and ofloxacin MICs ranging from 0.5 to 2 mg/L. The
551Arg mutation has been described as not being associated
with FQ resistance.36 Hence, we included all of them with the
WT isolates.
All but one (90Val) homogeneous QRDR mutants had gati-
floxacin MIC values .0.25 mg/L (Table 2). Among six gyrB
mutants, the 538Ser mutant had the highest gatifloxacin MIC
(.8 mg/L). Among pretreatment isolates only, 31%, 29% and
15% harboured 90Val, 94Gly and 94Ala mutations, respectively.
The highest gatifloxacin MIC values were observed for 94Gly
mutants, ranging from 2 to ≥16 mg/L, whereas both 90Val and
94Ala mutants tended to have somewhat lower MIC values, ran-
ging from 0.25 to 2 mg/L and from 0.5 to 2 mg/L, respectively
(with one exception each; Table 2). All nine either double gyrA
mutants or combined gyrA–gyrB mutants had MICs of ≥4 mg/L.
The 11 genetically heterogeneous populations (WT+mutant)
showed the entire range of MICs.
Isolates with WT QRDRs represented 16.4% of the phenotypic-
ally low-level gatifloxacin-resistant strains (MIC.0.5 to≤2 mg/L),
counting only one isolate per patient. Among the total of 208 iso-
lates with a WT QRDR sequence, 15 (7.2%) would be considered
resistant, with a gatifloxacin breakpoint to denote resistance
set at 0.5 mg/L and 11 (5.3%) if set at 1.0 mg/L. Applying the
WHO-recommended ≤1.0 mg/L (for 7H10 agar) to denote sus-
ceptibility would result in 32/102 (31.4%) homogeneous QRDR
mutants being classified as gatifloxacin-susceptible. The cumula-
tive number of strains plotted along the range of MICs tested37
reveals a maximum discrimination resistant/susceptible as
defined by QRDR status at 0.5 mg/L for gatifloxacin (Figure 3),
excluding isolates with documented heterogeneous populations.
To correlate characteristics of the respective pretreatment
M. tuberculosis isolates with treatment outcome, only one pre-
treatment isolate per patient was included. As ofloxacin has
become obsolete in MDR treatment, we limited our analysis to
patients treated with a gatifloxacin-based regimen. From these
223, 21 were excluded because of major modifications of the
standard treatment protocol, such as addition of linezolid, and 5
because of initial kanamycin resistance. To allow a fair assess-
ment of only patients who had a chance to fail or get cured, we
further excluded the 14 patients who died or absconded from
treatment and 2 because they had no gyrase result, leaving 181
patient-strains for genotypic-based analysis. For a sub-set analysis
on phenotypic correlation, 20 of the 181 were excluded because
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Figure 2. Censored regression analysis for MICs of the fourth-generation
FQs (gatifloxacin or moxifloxacin) versus ofloxacin. OFX, ofloxacin; GAT,
gatifloxacin; MXF, moxifloxacin. Gatifloxacin and moxifloxacin are right
censored above an MIC of 4 mg/L. Bubble sizes are proportional to case
density, using the square root of the case number in the stratum.
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they had no MIC determination of gatifloxacin, thus leaving 161
single-isolate patient-strains (Figure 1 and Table 3). Among the
excluded four patients who had died, two had a gyrA mutation
(90Val and 94Ala) while two yielded WT QRDR. Gatifloxacin MICs
ranged from ≤0.25 (1 WT) through 2 mg/L (90Val) to 4 mg/L
(94Ala and WT).
The odds of failing increased significantly with increasing pre-
treatment gatifloxacin resistance level (Pearson’s x2 test:
P,0.001; Cramer’s V: 0.654) (Table 3), with a drop in the propor-
tion cured to 50% or below starting from an MIC of 2 mg/L.
A comparison between gyrA mutations with gatifloxacin MICs
and treatment outcome showed that specific QRDR mutations
were associated with different MIC ranges, and that the presence
of QRDR mutations does not per se prevent cure with a high-dose
gatifloxacin-based regimen (Table 4). Gatifloxacin-based treat-
ment cured 94.1% of the 119 patients with WT isolates, whereas
this dropped to 50.0% in the presence of any mutation in the
QRDR (P,0.001). Heterogeneous QRDR mutations did not signifi-
cantly affect treatment outcome. The specific impact of gyrB
mutations could not be assessed in our study, as only three
gyrB mutations were not combined with a gyrA mutation.
Among the gyrA mutations, 90Val, 94Gly and 94Ala were the
most frequent, but their impact on cure differed. Any gyrA 94
mutation except 94Ala showed a cure proportion of only 30.8%,
Table 2. Correlation between observed mutations in the QRDRs of gyrA and gyrB genes and gatifloxacin MICs for 327 M. tuberculosis isolates from
patients prior to initiation and during follow-up of MDR treatment; this table includes all isolates for which gatifloxacin MICs were determined
gyrAB QRDRs
Gatifloxacin MIC (mg/L)
≤0.25 0.5 1 2 4 8 .8 total
Total 162 40 32 32 39 8 14 327
WT 160 33 4 3 8 0 0 208
gyrB mutation 6
535Met 0 1 1 0 0 0 0 2
538Ser 0 0 0 0 0 0 1 1
539Asn 0 0 1 0 0 0 0 1
539Ala 0 1 0 0 0 0 0 1
539Ile 0 0 0 1 0 0 0 1
Heterogeneous WT+gyrB mutation 1
WT+539Asn 0 0 0 1 0 0 0 1
gyrA mutation 96
74Ser 0 2 0 0 0 0 0 2
88Cys 0 0 0 1 0 1 0 2
89Asn 0 0 0 1 0 0 2 3
89Gly 0 0 1 0 0 0 0 1
90Val 1 2 14 12 0 0 1 30
91Pro 0 0 0 2 6 0 0 8
94Ala 0 1 7 5 1 0 0 14
94Asn 0 0 0 0 1 1 0 2
94Gly 0 0 0 5 16 5 2 28
94His 0 0 0 0 1 0 0 1
94Tyr 0 0 0 0 1 1 0 2
94Ala+37Val 0 0 0 0 1 0 0 1
94Asn+94Gly 0 0 0 0 1 0 0 1
90Val+91Pro 0 0 0 0 0 0 1 1
gyrA+B mutation 6
94Gly+540Arg 0 0 0 0 0 0 1 1
90Val+539Ala 0 0 0 0 1 0 0 1
94Tyr+538Ser 0 0 0 0 0 0 4 4
Heterogeneous WT+gyrA mutation 10
WT+89Asn 0 0 0 0 0 0 1 1
WT+90Val 0 0 1 1 0 0 0 2
WT+94Ala 1 0 2 0 0 0 0 3
WT+94Glya 0 0 1 0 2 0 1 4
aOne patient had an additional 538Asp mutation.
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whereas all remaining gyrAmutations taken together (all non-94
mutants+94Ala) resulted in successful high-dose gatifloxacin
treatment in 65.6% [P¼0.008; OR¼4.3 (CI 1.4–13.0)] (Table 4).
To further investigate the relevance of these findings within the
evaluated MDR-TB regimen, we assessed profiles of resistance to
the six accompanying drugs for all QRDR mutants. As specified in
our inclusion criteria, all isolates were susceptible to kanamycin.
Proportions of isolates resistant to high-dose isoniazid (1 mg/L),
ethambutol, ethionamide, pyrazinamide and clofazimine did not
differ significantly between cured and failed/relapsed patients
(Table 5). Similarly, cure proportions did not differ among isolates
resistant to one, two, three or four of the non-injectable accom-
panying drugs (Table 6).
Discussion
Based on our findings, an MIC .0.5 mg/L on LJ medium may be
an appropriate epidemiological cut-off for gatifloxacin and prob-
ably also moxifloxacin resistance, e.g. for a drug resistance preva-
lence survey. Assuming similar MIC values of FQs on LJ and agar
medium,3,38 the currently proposed 1 mg/L cut-off for gatifloxacin
(on 7H10 agar)38 would falsely classify too many isolates with a
mutation conferring drug resistance as susceptible, and should
thus be abandoned.
Importantly, our data suggest that MICs above the epidemio-
logical cut-off do not exclude high cure rates using a high-dose
gatifloxacin-based standard treatment regimen. Using high-dose
gatifloxacin regimens, cure rates considerably higher than those
reported elsewhere are achieved even in the presence of low-level
resistance (gatifloxacin MIC 1–2 mg/L).14 Because FQs are the key
drugs in MDR-TB treatment, it would be amistake not to use them
with this level of resistance. A drop in the proportion cured to
50% or below starts from a gatifloxacin MIC of 2 mg/L and
above. Given the4-fold higher MICvalues of ofloxacin compared
with gatifloxacin and moxifloxacin as observed in our study and
others,10,36 the gatifloxacin cut-offs of 0.5 and 2 mg/L correspond,
respectively, to the currently widely applied 2 mg/L and the less
applied 8 mg/L for ofloxacin. This suggests that for clinical pur-
poses a strategy of testing only one FQ drug, but with two concen-
trations, is entirely justified. Ourdata show that for gatifloxacin, and
probably also for moxifloxacin, this should be 0.5 and 2 mg/L on
LJ medium. Ofloxacin could be tested at 2 and 8 mg/L as the epi-
demiological and clinical cut-offs, respectively, for regimens using
more potent FQs at high dosage (gatifloxacin, possibly also moxi-
floxacin). Given the recent approval of bedaquiline and delamanid,
patients with gatifloxacin/moxifloxacin MICs .2 mg/L might be
more reliably cured by substituting one or the other of these
drugs. Identifying low-level FQ resistance, on the other hand,
may become important in the presence of resistance to injectable
drugs; this could not be determined from this dataset.
The strongest risk factor for a bacteriologically unfavourable out-
come with the Bangladesh regimen was high-level FQ resistance,
particularly when compounded by initial pyrazinamide resist-
ance.14 In our study population comprising only patients without
baseline resistance to kanamycin, treatment outcome was not
associated with resistance to companion drugs for the QRDR
mutants, corroborating the impact of high-level gatifloxacin resist-
ance. These proved to bemainlygyrA94mutants other than 94Ala.
We could not identify an obvious reason for treatment failure in
patients infected with isolates showing WT QRDR and low MICs,
which could be host and pathogen related. Patients were not coin-
fected with HIV and they did not have other overt comorbidities.
The main cause of treatment failure—both for non-MDR-TB and
MDR-TB—is non-adherence to treatment
The mechanism behind the differential impact of the different
substitutes is not fully understood. Piton et al.39 found amino acid
changes at position 94 to have a paradoxical effect on the resist-
ance level, with smaller residues like glycine or alanine or bulky
residues like tyrosine both increasing the resistance level. Using
protein structure analysis, we did not identify conclusive patterns
in differential GyrA protein stability for mutations that confer
different levels of phenotypic resistance (data available upon
request).
Also, we have no further explanation for the observed MIC
ranges within isolates harbouring the same QRDR mutation, a
phenomenon that has been observed for FQs in other studies15,40
and for other anti-TB drugs.41 It was not possible to determine
whether the background genotype influences the MIC conferred
by a specific mutation in this study.
Nevertheless, futuremolecular tests should thus not only allow
the differentiation of mutants from WT strains or identification of
Table 3. Cure versus failure/relapse for high-dose gatifloxacin-based
treatment stratified byMICvalues; only one pre-MDR-treatment isolate per
patient included
GAT MIC
(mg/L)
Failure/
relapse Cure Total
Percentage
cured
OR
to fail 95% CI
≤0.25 3 84 87 96.6 1
0.5 1 17 18 94.4 1.6 0.16–16.8
1 3 14 17 82.4 6.0 1.1–32.8
2 7 9 16 56.3 21.8 4.8–99.3
4 8 7 15 46.7 32.0 6.9–148.5
8 5 0 5 0.0 undef
.8 3 0 3 0.0 undef
Total 30 131 161 81.4
GAT, gatifloxacin; undef, undefined.
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Figure 3. Cumulative percentage of isolates in relation to the gatifloxacin
MIC, stratified by absence (WT) or presence of any QRDR mutation in the
gyrAB genes (11 heterogeneous populations excluded).
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the involved codon, but also permit differentiation betweenmuta-
tions in the same codon and the resulting amino acid change. Our
study offers strong evidence for a better treatment outcome in
the presence of 94Ala compared with 94Gly mutations. Other
codon-94 mutants were found only rarely and some of those
patients were cured, but their high MICs, comparable to those of
94Gly mutants, suggest that they should be classified with 94Gly
until there is more robust clinical documentation of a difference.
Even if some of the patients with 94Gly-mutant strains with an
intermediate MIC were treated successfully, a regimen modifica-
tion to include some of the new potent drugs might be most
appropriate to reduce the risk of acquisition of resistance to
Table 4. Summary of gatifloxacin treatment outcome stratified by gyrA-gyrB sequence result; only one pre-MDR-treatment isolate per patient included
gyrAB QRDRs Mutation type Cured
Failure/relapse
Totaln %
All strains 143 38 21.0 181
WTa 112 7 5.9 119
gyrB mutation only 535Met 0 1 100.0 1
gyrB mutation only 539Ala 1 0 0.0 1
gyrB mutation only 539Ile 0 1 100.0 1
WT+gyrB mutation WT+539Asn 1 0 0.0 1
gyrA mutation only 89Asn 1 0 0.0 1
gyrA mutation only 89Gly 0 1 100.0 1
gyrA mutation only 90Val 9 8 47.1 17
gyrA mutation only 94Ala 8 1 11.1 9
gyrA mutation only 94Asn 1 0 0.0 1
gyrA mutation only 94Gly 6 14 70.0 20
gyrA mutation only 94His 1 0 0.0 1
gyrA mutation only 94Tyr 0 3 100.0 3
gyrA+gyrB mutation 90Val+539Ala 1 0 0.0 1
WT+gyrA mutation WT+89Asn 0 1 100.0 1
WT+gyrA mutation WT+90Val 2 0 0.0 2
WT+gyrA mutation WT+94Glyb 0 1 100.0 1
Any gyrAB QRDR mutant 31 31 50.0 62
Any gyrA QRDR mutant 29 29 50.0 58
Any gyrA 94 mutant except 94Ala 8 18 69.2 26
Remaining gyrA mutants 21 11 34.4 32
Remaining gyrA mutants: all non-94 mutants+94Ala mutants; OR in 2×2 table shown in italics: 4.2 (95% CI 1.3–15.1).
aIncluding six with 234T (cured), one with 614His (cured), one with del 683–684 (cured) and three with 551Arg (two cured).
bFailure patient also has 538Asp mutation in gyrB gene.
Table 5. Resistance to accompanying drugs for 62 QRDR mutants stratified by gatifloxacin-based treatment outcome; only one pre-MDR-treatment
isolate per patient included
Cured Failed/relapsed
OR
95% CI
Pvalid result
resistant
valid result
resistant
low highn % n %
INH (1 mg/L on LJ medium) 31 30 96.8 27 27 100.0 inf NA NA 0.347
EMB (2 mg/L on LJ medium) 31 20 64.5 27 21 77.8 1.93 0.60 6.2 0.268
ETH (10 mg/L on Middlebrook 7H11 medium) 29 4 13.8 25 3 12.0 0.85 0.17 4.2 0.845
Rv0678 sequencing 30 5 16.7 16 1 6.3 0.33 0.04 3.1 0.318
pncA sequencing 31 20 64.5 19 15 78.9 2.06 0.55 7.8 0.280
INH, isoniazid; EMB, ethambutol; ETH, ethionamide; inf, infinite; NA, not applicable.
For pncA all mutations different from 65Ser were considered as resistant to pyrazinamide.
For Rv0678 all mutations were considered as potentially associated with clofazimine resistance.
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companion drugs and thus treatment failure or death.
Preliminary, unpublished results suggest that bedaquiline or line-
zolid can successfully replace high-dose fourth-generation FQs in
the context of high-level FQ resistance.
Any mutation at codon 94 can be identified by the only com-
mercial molecular test currently available (Genotype MTBDRsl;
Hain Lifesciences) by the absence of the WT3 probe, whereas
94Gly mutations can be detected specifically as MUT3C, and
94Ala as MUT3A. The WHO did not endorse this test due to poor
sensitivity, but our findings suggest that this may be useful after
all. In any case, the WHO supports the use of this test to identify
patients harbouring potentially high-level resistant codon-94
mutants in order to allow timely treatment adaptation.
The direct comparison between gatifloxacin and moxifloxacin
MICs suggested that the former might bemore active, confirming
recent data obtained by Li et al.36 and earlier observations.42
However, the pharmacokinetics of moxifloxacin are more favour-
able than those of gatifloxacin, with a very similar ratio of plasma
AUC to the MIC,43 suggesting equal in vivo potency at the same
dosage provided the AUC difference is the same in TB lesions.
These data support the use of gatifloxacin as the most potent
FQ, despite the dysglycaemia in Canadian elderly people (mean
age 78 years),44 which was not confirmed by more recent data
on the use of gatifloxacin in TB treatment, possibly because of a
substantially different, and notably far younger, population, likely
with a BMI less prone to pre-existing insulin resistance.14,45,46 The
Bangladesh patients tolerated the high-dose gatifloxacin well. It
remains to be seen whether similarly high bacteriological success
is obtainable with moxifloxacin, which on its own is associated
with potentially life-threatening adverse events.47
Our study confirms the rarity of gyrB mutations5,21,36 and does
not allow firm conclusions about their effect on MDR-TB treatment
when they are present. In addition, the phenotypically low-level
resistant strains with WT QRDR require further investigation to dis-
cover heterogeneous populations that remain below the detection
limit of classical target sequencing, and to elucidate alternative
mechanisms conferring FQ resistance in case of true WT QRDR.
Heterogeneous FQ resistance seems relatively frequent among
clinical isolates. Our sample size was too small to identify treat-
ment outcome differences between heterogeneous and homoge-
neous populations, but their MIC levels were in the same range.
Detection limits of different phenotypic and molecular assays
and platforms to find these heteroresistant populations remain
to be further investigated. The lack of data on levofloxacin is a limi-
tation of this study, as this remains the FQ of choice in many
recommended MDR-TB treatment regimens.
This study, based on a large dataset, provides an analysis of the
relationship between phenotypic and genotypic characteristics of
pretreatment isolates and the treatment outcome with a stan-
dardized MDR-TB treatment regimen. It suggests using 0.5 and
Table 6. Gatifloxacin-based treatment outcome for 62 patients with QRDR mutants stratified by resistance profile to accompanying drugs per isolate;
only one pre-MDR-treatment isolate per patient included
Resistance profile to accompanying drugs (KAN/INH/EMB/ETH/PZA/CFZ)
Number of isolates yielding a valid DST
result for the accompanying drugs
Cured Failed
n % n %
None or single drug 9 3 33.3 6 66.7
susceptible 4 0 4
ETH 1 1 0
INHa 4 2 2
Two drugs 25 13 52.0 12 48.0
INH/EMBb 14 6 8
INH/PZA 9 5 4
INH/CFZc 2 2 0
Subtotal for none, single drug or two drugs 34 16 47.1 18 52.9
Three drugs 21 10 47.6 11 52.4
INH/EMB/ETH 18 9 9
INH/EMB/PZAc 2 0 2
INH/PZA/CFZ 1 1 0
Four drugs 7 5 71.4 2 28.6
INH/EMB/ETH/PZA 4 3 1
INH/EMB/PZA/CFZ 3 2 1
Subtotal for three drugs or four drugs 28 15 53.6 13 46.4
Total 62 31 50.0 31 50.0
INH, isoniazid at 1 mg/L; EMB, ethambutol; ETH, ethionamide; KAN, kanamycin; PZA, pyrazinamide; CFZ, clofazimine.
Clofazimine and pyrazinamide were tested genotypically by sequencing Rv0678 and pncA genes, respectively.
aOne failure patient lacked clofazimine data.
bTwo failure and two cured patients lacked pyrazinamide or clofazimine data.
cOne cured patient lacked ethionamide data.
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2 mg/L as breakpoints for detecting low- and high-level resistance
to gatifloxacin/moxifloxacin on LJ medium, with high-level resist-
ance and gyrA-94 mutations other than Ala as predictors of poor
treatment outcome in pre-XDR patients.
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